Gland Pharma Ltd
NSE:GLAND

Watchlist Manager
Gland Pharma Ltd Logo
Gland Pharma Ltd
NSE:GLAND
Watchlist
Price: 1 596.95 INR -0.49% Market Closed
Market Cap: 263.1B INR

Gland Pharma Ltd
Investor Relations

Gland Pharma Ltd., an Indian company with a robust heritage, has made its mark in the global pharmaceutical landscape primarily through its adeptness in injectable medication. Founded in 1978 by P.V.N. Raju, the company’s journey has been one of steady ascension, characterized by a firm commitment to quality and innovation. Operating in a market where precision and reliability are paramount, Gland Pharma has specialized in the development and manufacturing of complex generic injectables, a niche that demands rigorous regulatory compliance and state-of-the-art manufacturing capabilities. With its extensive product portfolio, Gland Pharma serves a diverse range of therapeutic areas, including anti-coagulants, anti-biotics, and anti-virus medications, catering to hospitals and healthcare facilities worldwide. This strategic focus has enabled the company to build a reputable name in both domestic and international markets, becoming a critical supplier in the intricate supply chain of modern healthcare.

What distinguishes Gland Pharma from many contemporaries is its business model that hinges on backward integration and robust R&D capabilities. By taking charge of every aspect of production—from procuring raw materials to the final packaging—the company achieves cost efficiencies and ensures unwavering quality control. This integration extends beyond manufacturing, as Gland Pharma has cultivated strong relationships with strategic partners globally, facilitating its penetration into regulated markets such as the US, EU, and Australia. It harnesses these connections to distribute its products extensively while also acquiring ANDA (Abbreviated New Drug Application) approvals that cement its standing in these regions. Financially, Gland Pharma's revenue is largely derived from this steady export of generic injectables, riding on the ever-growing demand for affordable healthcare solutions. Through these strategic endeavors, the company encapsulates a blend of Indian manufacturing prowess and global pharmaceutical acumen, keeping its financial health robust and its market reach expansive.

Show more
Loading

Earnings Calls

2024 Q3
Nov 8, 2024
Show Transcript
Previous
Next
Bechtle Experiences Mixed Growth Amid Cost Pressures and Strategic Acquisitions
2024 Q3
Nov 8, 2024

In Q3 2024, Bechtle faced challenges with an overall 1.1% decline in business volume, primarily due to tough comparisons from a significant prior year software project. International growth was notable at 10.7%, while Germany saw an 8% drop. Revenue rose 2.2%, partially misleading due to past benchmarks. Despite cost pressures from personnel and operating expenses, cash flow from operations improved to nearly EUR 290 million. Bechtle's employee count grew 5.2% year-over-year. The company anticipates a stronger Q4, focusing on growth from M&A initiatives and public sector clients, although overall financial performance for the year remains below expectations.

Show Full Analysis

Management

Mr. Srinivas Sadu
CEO & Executive Chairman
No Bio Available
Mr. Ravi Shekhar Mitra
Chief Financial Officer
No Bio Available
Mr. Sampath Kumar Pallerlamudi
Company Secretary & Vice-President of Compliance & CSR
No Bio Available
Mr. Satnam Singh Loomba
Chief Operating Officer
No Bio Available
Mr. Ankit Gupta
Head of Investments, Strategy & Investor Relations
No Bio Available
Mr. Surinder Koul
Head of Domestic Marketing
No Bio Available
Mr. K Raghuramachandra Rao
Head of Quality
No Bio Available
Mr. R.V.R. Prabhakara Sastry
Senior Vice President of R&D
No Bio Available
Mr. Rong Wu
Chief Financial Controller
No Bio Available

Contacts

Address
TELANGANA
Hyderabad
Survey No. 143-148, 150 & 151, Near Gandimaisamma 'X' Roads, D.P. Pally, Dundigal Gandimaisamma Mandal Medchal-Malkajgiri District
Contacts
+914030510999
www.glandpharma.com